Voltaren Arthritis Pain and the Arthritis Foundation Announce Multi-Year Partnership to Help People Living with Osteoarthritis
GlaxoSmithKline PLC (GSK)
US:NYSE Investor Relations:
gsk.com/en-gb/investors
Company Research
Source: PR Newswire
WARREN, N.J., April 13, 2020 /PRNewswire/ -- GlaxoSmithKline (LSE/NYSE: GSK) today announced a multi-year partnership with the Arthritis Foundation to support scientific research, advocacy as well as virtual resources and community connections for the more than 30 million people in America living with osteoarthritis (OA) 1. As part of the mission for an osteoarthritis cure, Voltaren Arthritis Pain is donating 100 percent of profits from pre-order of the product, which is the first and only prescription strength nonsteroidal anti-inflammatory (NSAID) topical gel for arthritis pain to be available over the counter, beginning today through May 12, to support the Arthritis Foundation's goal to provide virtual care and connection to their patient community during the coronavirus (COVID-19) pandemic. Osteoarthritis, which occurs when the cartilage between joints begins to break down and wear away, is one of the leading causes of disability in the U.S., affecting 1 in 7 adults2. For the mill
Show less
Read more
Impact Snapshot
Event Time:
GSK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GSK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GSK alerts
High impacting GlaxoSmithKline PLC news events
Weekly update
A roundup of the hottest topics
GSK
News
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- GSK (NYSE:GSK) was upgraded by analysts at Bank of America Corporation from an "underperform" rating to a "neutral" rating.MarketBeat
- GSK (NYSE:GSK) had its "buy (b)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Deutsche Bank Maintains a Hold Rating on GSK plc (GSK) [Yahoo! Finance]Yahoo! Finance
- GSK (NYSE:GSK) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "hold (c+)" rating to a "buy (b-)" rating.MarketBeat
GSK
Sec Filings
- 12/5/25 - Form 6-K
- 12/4/25 - Form 6-K
- 12/3/25 - Form 6-K
- GSK's page on the SEC website